Business Wire - Mylan Receives Approval for Tizanidine Hydrochloride Tablets
April 1, 2003 -- Business Editors/Medical Writers PITTSBURGH--(BUSINESS WIRE)--April 1, 2003 Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food...
Business Wire - Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
April 3, 2008 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that John Librie has been promoted to Senior Vice President, Sales and...
Business Wire - Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results
February 11, 2008 -- * Lead clinical product, Fampridine-SR, entered and completed enrollment for second Phase 3 clinical trial in multiple sclerosis (MS); data expected...
Business Wire - Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial of Fampridine-SR
November 30, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it has completed enrollment for its Phase 3 clinical trial of...
Business Wire - Acorda Therapeutics Files Lawsuit Against Apotex Corp. and Apotex Inc. Relating to Zanaflex Capsules
October 11, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has filed a lawsuit against Apotex Corp. and Apotex Inc. in the...
Business Wire - Acorda Therapeutics Announces Receipt of ANDA Filing for Zanaflex Capsules
September 6, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has received a Paragraph IV Certification Notice from Apotex Inc....
M2 Presswire - Acorda Therapeutics Receives and Responds to Third Point Letter.
February 26, 2007 -- M2 PRESSWIRE-26 February 2007-Headline Maker: Acorda Therapeutics Receives and Responds to Third Point Letter(C)1994-2007 M2 COMMUNICATIONS LTD...
Business Wire - Acorda Therapeutics Responds to Third Point Letter
February 23, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced today that it has received a letter from Third Point LLC dated February 22,...
Business Wire - Acorda Therapeutics Receives Additional $5 Million from Paul Capital Healthcare
February 7, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics (NASDAQ: ACOR) announced today that it has received a second, $5 million payment as part of its agreement with...
Business Wire - Acorda Therapeutics Announces Completion of Zanaflex Capsules™ Sales Force Expansion
January 8, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc.([R]) (Nasdaq: ACOR) reported today that it has completed the previously announced expansion of its sales...
